Compare CVS Health Corp (CVS) vs MasTec Inc (MTZ) Price & Performance

CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.

The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.

MasTec (MTZ) trades at $360.21, down 3.4% on the day, with a bearish technical signal despite strong fundamental performance. The company recently announced a $1.65 billion acquisition of The Superior Group to expand its data center infrastructure capabilities, boosting its position in AI-driven markets. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 showing 34% revenue growth and 73% adjusted EBITDA growth, supported by a record $20.3 billion backlog.

Wall Street maintains strong bullish sentiment with 89% buy ratings and a $481.77 consensus price target suggesting 34% upside potential. Key risks include integration challenges from the large acquisition and premium valuation metrics. The stock's current weakness presents a potential buying opportunity for investors bullish on infrastructure spending trends.